Please Subscribe to get a daily link to Pat's blog via email

Subscribe!

Your privacy is important to us. We will never spam you and keep your personal data secure.

Looks like carfilzomib has a trade name: Kyprolis

Home/Research, Supplements/Drugs/Looks like carfilzomib has a trade name: Kyprolis

Looks like carfilzomib has a trade name: Kyprolis

Trade names normally aren’t established and trademarked until after FDA preliminary approval of a drug.  Looks like our friends at Onyx are pretty confident that the FDA will step-up and quickly approve carfilzomib for relapsed/refractory myeloma patients.

Keeping that in mind, here is the upcoming trial data presentation schedule for carfilzomib at next month’s ASCO meetings in Chicago:

Onyx Pharmaceuticals Announces Data Presentations at 48th American Society of Clinical Oncology Annual Meeting

Kyprolis™ (proposed trademark for carfilzomib)

Response rates to single-agent carfilzomib in patients refractory or intolerant to both bortezomib and immunomodulators in trial PX-171-003-A1

  • Dr. David S. Siegel, Hackensack University Medical Center, United States
  • Saturday, June 2, 2012
  • Poster viewing: 8:00 AM – 12:00 PM, E450b
  • Poster discussion: 12:00 PM-1:00 PM, E354a
  • Poster discussion session –  Lymphoma and Plasma Cell Disorders, Poster #15
  • Abstract #8035

Phase I/II study of carfilzomib plus melphalan-prednisone (CMP) in elderly patients with de novo multiple myeloma

  • Dr. Brigitte Kolb, University Hospital, Nantes, France
  • Sunday, June 3, 2012
  • Oral presentation: 8:00 AM – 8:15 AM, E354a
  • Oral Abstract Session – Myeloma
  • Abstract #8009

A Phase I/II trial of cyclophosphamide, carfilzomib, thalidomide and dexamethasone (CYCLONE) in patients with newly diagnosed multiple myeloma

  • Dr. Joseph Mikhael, Mayo Clinic, United States
  • Sunday, June 3, 2012
  • Oral presentation: 8:15 AM – 8:30 AM, E354a
  • Oral Abstract Session – Myeloma
  • Abstract #8010

Stringent complete response (sCR) in patients (pts) with newly diagnosed multiple myeloma (NDMM) treated with carfilzomib (CFZ), lenalidomide (LEN), and dexamethasone (DEX)

  • Dr. Andrzej J. Jakubowiak, University of Chicago, United States
  • Sunday, June 3, 2012
  • Oral presentation: 8:30 AM – 8:45 AM, E354a
  • Oral Abstract Session – Myeloma
  • Abstract #8011

Hematologic safety data from four phase II studies of single-agent carfilzomib in relapsed and/or refractory multiple myeloma

  • Dr. Ajay K. Nooka,  Emory University School of Medicine, United States
  • Monday, June 4, 2012
  • Poster time: 1:15 PM – 5:15 PM, S Hall A2
  • General poster session – Lymphoma and Plasma Cell Disorders, Poster #37C
  • Abstract #8086

A phase I/II study of carfilzomib (CFZ) as a replacement for bortezomib (BTZ) for multiple myeloma (MM) patients (Pts) progressing while receiving a BTZ-containing combination regimen

  • Dr. James R. Berenson, Institute for Myeloma and Bone Cancer Research (IMBCR), United States
  • Monday, June 4, 2012
  • Poster time: 1:15 PM – 5:15 PM, S Hall A2
  • General poster session – Lymphoma and Plasma Cell Disorders, Poster #38G
  • Abstract #8098

A single-arm, open-label, multicenter phase I/II study of the combination of panobinostat (pan) and carfilzomib (cfz) in patients (pts) with relapsed/refractory multiple myeloma (RR MM)

  • Dr. Jesus G. Berdeja, Sarah Cannon Research Institute, United States
  • Monday, June 4, 2012
  • Poster time: 1:15 PM – 5:15 PM, S Hall A2
  • General poster session – Lymphoma and Plasma Cell Disorders, Poster #40H
  • Abstract #TPS8115

Is there better than expected results buried somewhere within all of this data?  Could that be why Onyx officials seem so confident?

I will be in Illinois, covering ASCO.  Stay tuned!

Feel good and keep smiling!  Pat